Skip to main content
Terug
Watch Compare

LakeShore Biopharma Co., Ltd.

Datakwaliteit: 100%
Ook genoteerd als LSBWF OTC
LSBCF
OTC Manufacturing Chemicals
€ 0,03
▼ € 0,04 (-55,71%)
Marktkapitalisatie: 2,88 M
Prijs
€ 0,07
Marktkapitalisatie
2,88 M
Dagbereik
—
52-Weeksbereik
—
Volume
—
Openen —
50D / 200D Gem.
—
50D / 200D Gem.
—

Quick Summary

Belangrijkste Punten

Negative free cash flow of -18,62 M
Capital efficient — spends only 2,07% of revenue on capex

Groei

Revenue Growth (5Y)
N/A
Revenue (1Y)6,00%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-18,31%
Boven sectorgemiddelde (-54,01%)
ROIC-6,90%
Net Margin-16,26%
Op. Margin-14,03%

Veiligheid

Debt / Equity
0,83
Boven sectorgemiddelde (0,30)
Current Ratio1,02
Interest Coverage-5,48

Waardering

PE (TTM)
-0,21
Boven sectorgemiddelde (-1,49)
P/B Ratio0,04
EV/EBITDAN/A
Dividend YieldN/A

Koershistorie

Financiële Trends

Sectorvergelijking

vs Manufacturing sector mediaan (1385 peers)
Metriek Aandeel Sector Mediaan
P/E -0,2 -1,5
P/B 0,0 1,6
ROE % -18,3 -54,0
Net Margin % -16,3 -41,5
Rev Growth 5Y % — 1,8
D/E 0,8 0,3

Koersdoel Analisten

Geen analistendekking beschikbaar

Winstschattingen

Geen toekomstige schattingen beschikbaar

Winstverassingen

Laatste 4 kwartalen
Kwartaal Geschat WPA Werkelijk WPA Verrassing
Q12024 -€ 5,80 -€ 13,40 -131,0%
Q42023 -€ 4,20 -€ 8,30 -97,6%
Q32023 -€ 6,20 -€ 11,28 -82,0%
Q22023 N/A -€ 7,50 —

All Fundamental Metrics
Growth
Revenue Growth (1Y) 6,00% Revenue Growth (3Y) -7,44%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 85,67 M Net Income (TTM) -13,93 M
ROE -18,31% ROA -6,90%
Gross Margin 82,47% Operating Margin -14,03%
Net Margin -16,26% Free Cash Flow (TTM) -18,62 M
ROIC -6,90% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,83 Current Ratio 1,02
Interest Coverage -5,48 Asset Turnover 0,42
Working Capital 2,43 M Tangible Book Value 59,47 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -0,21 Forward P/E N/A
P/B Ratio 0,04 P/S Ratio 0,03
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -645,59%
Market Cap 2,88 M Enterprise Value 60,55 M
Per Share
EPS (Diluted TTM) -0,73 Revenue / Share 2,08
FCF / Share -0,45 OCF / Share -0,41
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue 2,07% FCF Conversion 133,71%
SBC-Adj. FCF -20,51 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023
Revenue 85,67 M 80,82 M 100,00 M
Net Income -13,93 M -61,09 M -21,17 M
EPS (Diluted) -0,73 -0,57 -0,23
Gross Profit 70,66 M 64,23 M 77,69 M
Operating Income -12,02 M -62,84 M -20,28 M
EBITDA — — —
R&D Expenses 20,39 M 42,68 M 46,38 M
SG&A Expenses — — —
D&A — — —
Interest Expense -2,19 M -6,25 M -4,49 M
Income Tax -131.910,0 -3,06 M 164.952,0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023
Total Assets 190,53 M 213,25 M 250,27 M
Total Liabilities 120,91 M 130,77 M 144,26 M
Shareholders' Equity 69,62 M 82,48 M 106,01 M
Total Debt 57,67 M 58,85 M 42,75 M
Cash & Equivalents — — 53,90 M
Current Assets 117,33 M 127,30 M 150,76 M
Current Liabilities 114,90 M 113,07 M 95,87 M